Immunocore Holdings plc

Welcome to the Immunocore conference call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Clayton Robertson, Head of Investor Relations. Thank you. You may begin.

Good morning and good afternoon. Thank you for joining us on our Q2 and first half 2024 earnings call today. During today's call, we'll make some forward-looking statements which are qualified by our safe harbor provision under the Private Securities Litigation Reform Act of 1995. Please note that actual results can vary materially from those indicated by these forward-looking statements, including those discussed in our filings with the SEC. On today's call, I'm joined by Baheja Jalal, CEO of Immunocore, and Brian DiDonato, CFO and Head of Strategy, who will share a strategy update. Ralph Torbay, Head of Commercial, will review our first half ChemTrack sales and additional growth opportunities for ChemTrack. David Berman, Immunocore's Head of RD, will provide some pipeline updates. including near-term readouts in oncology and infectious diseases. Brian will also provide highlights on our financial results reported this morning. Adhija.

Thank you, Clay. As you may be able to hear, I'm losing my voice and I have pharyngitis. So to be able to answer your questions at the end, I will ask Brian to pitch it for me. Brian, please.